ABUSArbutus Biopharma CorpHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $5.05 · now $5.05 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ABUS has typically landed between $4.19 and $6.29 — a range of −17.0% to +24.6% from the issuance price $5.05.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,794 overlapping 1 month windows · 2007-07-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.05) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ABUS has typically landed a month from the 2026-09-16 close of $5.05 — the range is history, not a prediction.

$4.19worst · -17.0%$6.29best · +24.6%
  • now $5.05 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $5.03 (-0.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.62$5.43
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.19$6.29
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,794 windows spanning 2007-07-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-03-05−69.7%−69.7%+0.0%
2020-03-04−67.0%−67.0%+0.0%
2020-03-06−65.0%−69.4%+0.0%
3 best
2020-06-23+142.0%−14.6%+142.0%
2020-07-07+134.9%−5.9%+166.7%
2014-07-11+129.5%−13.4%+129.5%

4,794 overlapping windows · 2007-07-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
58%
+12.2%
n=19
Feb
58%
+4.9%
n=19
Mar
53%
−1.9%
n=19
Apr
47%
−2.0%
n=19
May
53%
+8.9%
n=19
Jun
42%
−3.7%
n=19
Jul
47%
+12.5%
n=19
Aug
35%
−0.2%
n=20
Sep
50%
+4.5%
n=20
Oct
26%
−6.8%
n=19
Nov
42%
+0.2%
n=19
Dec
21%
−0.5%
n=19

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$5$3↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-02-04McElhaugh Michael J.directorSale23,790 @ $3.28$78K−1.6% of holding+5.1%−2.5%1,481,003Form 4 · filed 1 day after the trade
2025-02-04HASTINGS DAVID CdirectorSale22,183 @ $3.28$73K−12.2% of holding+5.1%−2.5%159,724Form 4 · filed 1 day after the trade
2025-02-04Sims KarenofficerSale19,348 @ $3.28$64K−15.4% of holding+5.1%−2.5%106,194Form 4 · filed 1 day after the trade
2025-02-04Naftzger J. ChristopherofficerSale11,333 @ $3.28$37K−11.6% of holding+5.1%−2.5%86,244Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

19 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-08Beardsley Robert AdirectorAward / grant78,80078,800Form 4
2026-06-08Sawhney RogerdirectorAward / grant78,80078,800Form 4
2026-02-02Androski LindsaydirectorAward / grant28,00028,000Form 4
2026-02-02Androski LindsaydirectorAward / grant71,70071,700Form 4
2026-02-02Nguyen TuanofficerAward / grant73,50073,500Form 4
2026-02-02Nguyen TuanofficerAward / grant188,400188,400Form 4
2025-08-04Sawhney RogerdirectorAward / grant157,600157,600Form 4
2025-03-31Nguyen TuanofficerAward / grant750,000750,000Form 4
2025-03-18Hasija AnujdirectorAward / grant157,600157,600Form 4
2025-03-18Beardsley Robert AdirectorAward / grant157,600157,600Form 4
2025-03-18Androski LindsaydirectorAward / grant310,422310,422Form 4
2025-02-14Naftzger J. ChristopherofficerAward / grant220,300220,300Form 4
2025-02-14HASTINGS DAVID CdirectorAward / grant365,800365,800Form 4
2025-02-14McElhaugh Michael J.directorAward / grant177,0001,658,003Form 4
2025-02-14McElhaugh Michael J.directorAward / grant718,800718,800Form 4
2025-02-14Naftzger J. ChristopherofficerAward / grant54,300140,544Form 4
2025-02-14Sims KarenofficerAward / grant49,300155,494Form 4
2025-02-14Sims KarenofficerAward / grant200,300200,300Form 4
2025-02-14HASTINGS DAVID CdirectorAward / grant90,100249,824Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.